Impact of the COVID-19 pandemic on inpatient antibiotic use in Indonesia and the Philippines

Background: The coronavirus disease 2019 (COVID-19) pandemic severely affected Southeast Asia, with >35 million cases and ~360,000 deaths. Despite relatively low rates of secondary bacterial infection among inpatients with COVID-19, several countries reported increased antibiotic use; raising con...

Full description

Saved in:
Bibliographic Details
Main Authors: Amara Fazal (Author), Olivia McGovern (Author), Garrett Mahon (Author), Fernanda Lessa (Author), Ma Tarcela Gler (Author), Jemelyn Garcia (Author), Mark Festin (Author), Kuntaman Kuntaman (Author), Ida Parwati (Author), Cherry Siregar (Author), Jay Christian (Author), Gina de Guzman Betito (Author), Maya Montemayor (Author), Arleen De Leon (Author), Emmeline Borillo (Author), Mark Llanes (Author), Regina Berba (Author), Musofa Rusli (Author), Farizal Rizky (Author), Mariyatul Qibtiyah (Author), Bambang Semedi (Author), Rosantia Sarassari (Author), Leonardus Widyatmoko (Author), Basti Andriyoko (Author), Adhi Sugianli (Author), Dewi Turbawaty (Author), Ivo Ranita (Author), Franciscus Ginting (Author), Made Krisna (Author), Rahmadania Marita Joesoef (Author), Twisha Patel (Author)
Format: Book
Published: Cambridge University Press, 2023-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_cf4fe4e081084a68b3f84c0bd59e8c8c
042 |a dc 
100 1 0 |a Amara Fazal  |e author 
700 1 0 |a Olivia McGovern  |e author 
700 1 0 |a Garrett Mahon  |e author 
700 1 0 |a Fernanda Lessa  |e author 
700 1 0 |a Ma Tarcela Gler  |e author 
700 1 0 |a Jemelyn Garcia  |e author 
700 1 0 |a Mark Festin  |e author 
700 1 0 |a Kuntaman Kuntaman  |e author 
700 1 0 |a Ida Parwati  |e author 
700 1 0 |a Cherry Siregar  |e author 
700 1 0 |a Jay Christian  |e author 
700 1 0 |a Gina de Guzman Betito  |e author 
700 1 0 |a Maya Montemayor  |e author 
700 1 0 |a Arleen De Leon  |e author 
700 1 0 |a Emmeline Borillo  |e author 
700 1 0 |a Mark Llanes  |e author 
700 1 0 |a Regina Berba  |e author 
700 1 0 |a Musofa Rusli  |e author 
700 1 0 |a Farizal Rizky  |e author 
700 1 0 |a Mariyatul Qibtiyah  |e author 
700 1 0 |a Bambang Semedi  |e author 
700 1 0 |a Rosantia Sarassari  |e author 
700 1 0 |a Leonardus Widyatmoko  |e author 
700 1 0 |a Basti Andriyoko  |e author 
700 1 0 |a Adhi Sugianli  |e author 
700 1 0 |a Dewi Turbawaty  |e author 
700 1 0 |a Ivo Ranita  |e author 
700 1 0 |a Franciscus Ginting  |e author 
700 1 0 |a Made Krisna  |e author 
700 1 0 |a Rahmadania Marita Joesoef  |e author 
700 1 0 |a Twisha Patel  |e author 
245 0 0 |a Impact of the COVID-19 pandemic on inpatient antibiotic use in Indonesia and the Philippines 
260 |b Cambridge University Press,   |c 2023-06-01T00:00:00Z. 
500 |a 10.1017/ash.2023.209 
500 |a 2732-494X 
520 |a Background: The coronavirus disease 2019 (COVID-19) pandemic severely affected Southeast Asia, with >35 million cases and ~360,000 deaths. Despite relatively low rates of secondary bacterial infection among inpatients with COVID-19, several countries reported increased antibiotic use; raising concerns for worsening antimicrobial resistance. We assessed the impact of the COVID-19 pandemic on the use of antibiotics commonly used to treat respiratory infections in Southeast Asia. Methods: We evaluated intravenous antibiotic use among hospitalized adults in acute-care wards in 6 hospitals; 3 in Indonesia and 3 in the Philippines. We abstracted data on antibiotics that are commonly used to treat respiratory infections in these hospitals. We calculated antibiotic use rates for the 25 included antibiotics as monthly defined daily dose per 1,000 patient days (or patient discharges where patient days was unavailable) using data from pharmacy dispensing records and administrative records. Median antibiotic use rates for the prepandemic period (March 2018-February 2020) and the pandemic period (March 2020-February 2021) were compared, and percentage changes were calculated for (1) all 25 antibiotics combined; (2) ceftriaxone; (3) vancomycin and linezolid combined (anti-MRSA); and (4) broad-spectrum antibiotics with activity against Pseudomonas aeruginosa (anti-PSA). Monthly antibiotic use and COVID-19 patient discharges were graphed over the 36-month study period (March 2018-February 2021) to visualize trends (Fig. 1). The Wilcoxon rank-sum test was used to determine whether differences in median antibiotic use rates were statistically significant (2-tailed P < .05). Results: Overall, trends in antibiotic use were higher during months with increased COVID-19 patient discharges (Fig. 1). Use of all 25 antibiotics combined significantly increased in 4 of 6 hospitals (6.9%-63.6%) during the pandemic period compared to the prepandemic period. Ceftriaxone use significantly increased in 3 of 6 hospitals (37.1%-55.4%) and decreased in 3 of 6 hospitals (15.9%-31.9%). Anti-PSA antibiotic use significantly increased in 4 of 6 hospitals (16.1%-161.5%). Although anti-MRSA antibiotic use was low (comprising <2% of the overall included antibiotic use in Indonesia and <11% in the Philippines), use during the pandemic increased in 3 of 6 hospitals (59.8%-212.6%). Conclusions: We observed substantial increases in antibiotic use among hospitalized adults in Indonesia and the Philippines during the COVID-19 pandemic. The increased use of broad-spectrum antibiotics is concerning given the potential consequence of worsening antimicrobial resistance. Understanding how increases in antibiotic use compares to rates of bacterial infection, antimicrobial resistance, and antibiotic availability and accessibility during this time is important to contextualize results. These findings reinforce the importance of antibiotic stewardship practices to optimize antibiotic use, especially during pandemics. 
546 |a EN 
690 |a Infectious and parasitic diseases 
690 |a RC109-216 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Antimicrobial Stewardship & Healthcare Epidemiology, Vol 3, Pp s1-s2 (2023) 
787 0 |n https://www.cambridge.org/core/product/identifier/S2732494X23002097/type/journal_article 
787 0 |n https://doaj.org/toc/2732-494X 
856 4 1 |u https://doaj.org/article/cf4fe4e081084a68b3f84c0bd59e8c8c  |z Connect to this object online.